Paper28928126
Chimeric antigen receptor T-cell therapies for multiple myeloma.
Mikkilineni L and 1 other. Blood, 2017. Cited by 185 papers, by iCite.
Cite this record
ConductScience Library. Chimeric antigen receptor T-cell therapies for multiple myeloma. Papers, record 28928126. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28928126
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Receptors, Antigen, T-Cell | Major topic |
| Recombinant Fusion Proteins | Major topic |
| T-Lymphocytes | Major topic |
| Antigens, CD19 | |
| Humans | |
| Immunotherapy, Adoptive | |
| Neoplastic Stem Cells | |
| Plasma Cells |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIABC011439 | NIH |
Source NIH RePORTER
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03778346 | Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells | Background |
Source ClinicalTrials.gov
References92
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22160384 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. | Blood | 2012 | https://conductscience.org/library/papers/22160384 | PubMed |
| 2 | 28291388 | Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28291388 | PubMed |
| 3 | 27207799 | Toxicities of chimeric antigen receptor T cells: recognition and management. | Blood | 2016 | https://conductscience.org/library/papers/27207799 | PubMed |
| 4 | 26726943 | Allogeneic stem cell transplantation for multiple myeloma: is there a future? | Bone Marrow Transplant | 2016 | https://conductscience.org/library/papers/26726943 | PubMed |
| 5 | 29061640 | Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29061640 | PubMed |
| 6 | 7913116 | Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule. | J Immunol | 1994 | https://conductscience.org/library/papers/7913116 | PubMed |
| 7 | 19047103 | Preclinical characterization of SGN-70, a humanized antibody directed against CD70. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/19047103 | PubMed |
| 8 | 25995224 | Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/25995224 | PubMed |
| 9 | 6460831 | Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. | J Exp Med | 1982 | https://conductscience.org/library/papers/6460831 | PubMed |
| 10 | 22766978 | Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. | Int J Oncol | 2012 | https://conductscience.org/library/papers/22766978 | PubMed |
| 11 | 24311149 | Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. | Int J Hematol | 2014 | https://conductscience.org/library/papers/24311149 | PubMed |
| 12 | 27270177 | Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27270177 | PubMed |
| 13 | 19561539 | Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. | J Immunother | 2009 | https://conductscience.org/library/papers/19561539 | PubMed |
| 14 | 24876563 | Current concepts in the diagnosis and management of cytokine release syndrome. | Blood | 2014 | https://conductscience.org/library/papers/24876563 | PubMed |
| 15 | 16203864 | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. | J Exp Med | 2005 | https://conductscience.org/library/papers/16203864 | PubMed |
| 16 | 24055823 | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. | Blood | 2013 | https://conductscience.org/library/papers/24055823 | PubMed |
| 17 | 10931011 | Controversies surrounding the clonogenic origin of multiple myeloma. | Br J Haematol | 2000 | https://conductscience.org/library/papers/10931011 | PubMed |
| 18 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 19 | 21830940 | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21830940 | PubMed |
| 20 | 27998219 | How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27998219 | PubMed |
Cited by145
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42157940 | Immunologic Combinations in Multiple Myeloma: Synergistic Stimulation with T cells and NK cells. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42157940 | PubMed |
| 41617828 | Generation of TCRγδ + T cells from human embryonic stem cells. | Sci Rep | 2026 | https://conductscience.org/library/papers/41617828 | PubMed |
| 41455063 | Current Developments of CAR-T and CAR-NK Cell Therapies for Ovarian Cancer. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/41455063 | PubMed |
| 41303706 | State of the Art of CAR-NK Cell Therapy in Multiple Myeloma: A Comprehensive Review of Cell Sources and Target Antigens. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41303706 | PubMed |
| 41228344 | High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T). | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41228344 | PubMed |
| 40627450 | CAR-engineered cytolytic Tregs reverse pulmonary fibrosis and remodel the fibrotic niche with limited CRS. | JCI Insight | 2025 | https://conductscience.org/library/papers/40627450 | PubMed |
| 40619794 | Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods. | Balkan Med J | 2025 | https://conductscience.org/library/papers/40619794 | PubMed |
| 40606990 | Cardiovascular adverse effects of immunotherapy in cancer: insights and implications. | Front Oncol | 2025 | https://conductscience.org/library/papers/40606990 | PubMed |
| 40433368 | Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies. | Front Immunol | 2025 | https://conductscience.org/library/papers/40433368 | PubMed |
| 40029598 | Immune Cell Homing Hydrogels for Cancer Immunotherapy. | Methods Mol Biol | 2025 | https://conductscience.org/library/papers/40029598 | PubMed |
| 39957814 | Advancing Multiple Myeloma Immunotherapy: A Review of Chimeric Antigen Receptor T-Cell and Bispecific T-Cell Engagers Cell Therapies in Revolutionizing Treatment. | Iran J Med Sci | 2025 | https://conductscience.org/library/papers/39957814 | PubMed |
| 39901537 | A Systematic Review and Meta-analysis on the Safety and Efficacy of CAR T Cell Therapy Targeting GPRC5D in Patients with Multiple Myeloma: A New Insight in Cancer Immunotherapy. | Anticancer Agents Med Chem | 2025 | https://conductscience.org/library/papers/39901537 | PubMed |
| 39893165 | Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. | Nat Commun | 2025 | https://conductscience.org/library/papers/39893165 | PubMed |
| 39692978 | Revolutionizing cancer treatment: the rise of personalized immunotherapies. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39692978 | PubMed |
| 39625587 | CAR T-cell therapy to treat multiple myeloma: current state and future directions. | Cancer Metastasis Rev | 2024 | https://conductscience.org/library/papers/39625587 | PubMed |
| 39614361 | BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma. | J Transl Med | 2024 | https://conductscience.org/library/papers/39614361 | PubMed |
| 39592597 | CAR-T cell therapy in Multiple Myeloma: current status and future challenges. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/39592597 | PubMed |
| 39290982 | Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review. | Ther Adv Hematol | 2024 | https://conductscience.org/library/papers/39290982 | PubMed |
| 38964917 | [Construction of CD138-targeted chimeric antigen receptor- modified T cells and their effect in multiple myeloma therapy]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | https://conductscience.org/library/papers/38964917 | PubMed |
| 38651157 | Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis. | Front Oncol | 2024 | https://conductscience.org/library/papers/38651157 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| CXADRP1 | 653108 | PubTator's text mining | https://conductscience.org/library/genes/653108 | NCBI Gene |
| SDC1 | 6382 | PubTator's text mining | https://conductscience.org/library/genes/6382 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28928126
GET https://conductscience.org/api/papers/v1/28928126/references?page=2